Drug intelligence / Profile preview

BBRP11051

Development stage: Preclinical
Lead developer: Benobio
Modality: Small Molecules

Overview

BBRP11051 is a small molecule drug under preclinical development by Benobio for the treatment of inflammatory bowel disease. The compound is being developed in South Korea and targets digestive system disorders, specifically aiming to address conditions within the spectrum of inflammatory bowel diseases. Detailed information about its mechanism of action or molecular target has not been disclosed publicly as of June 2025[1][2][3].

Targets

FFAR4 (Free fatty acid receptor 4)

Beyond the preview

Go deeper on BBRP11051.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BBRP11051.

Explore the full profile